<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65630">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02141438</url>
  </required_header>
  <id_info>
    <org_study_id>16913</org_study_id>
    <nct_id>NCT02141438</nct_id>
  </id_info>
  <brief_title>Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer</brief_title>
  <acronym>REASSURE</acronym>
  <official_title>Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study in the routine clinical practice setting to evaluate the short and long
      term safety profile of Radium-223 in metastatic castration resistant prostate cancer
      patients and to evaluate the risk of developing second primary cancers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of developing second primary malignancies</measure>
    <time_frame>From study start to 7 years post last dose of Radium-223</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent SAEs</measure>
    <time_frame>From study start up to 30 days after the last administration of Radium-223</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of drug-related treatment-emergent adverse events</measure>
    <time_frame>From study start up to 30 days after the last administration of Radium-223</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of drug-related SAEs</measure>
    <time_frame>From study start to 7 years post last dose of Radium-223</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marrow suppression</measure>
    <time_frame>From study start to 7 years post last dose of Radium-223</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Therapeutic/prevention measures/treatment modalities, Gr. 3/4 hematological toxicities (up to 6 months after last administration), platelet or WBC &lt; lower limit of normal during treatment +30 days will be followed to resolution (up to 6 months after last administration), and febrile neutropenia and hemorrhage for patients who start subsequent chemotherapy will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From study start to 7 years post last dose of Radium-223</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The worst pain score and pain interference score over time as determined by patient responses on the &quot;Brief pain inventory short form&quot; (BPI-SF) questionnaire</measure>
    <time_frame>From study start to 6 months post last dose of Radium-223</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1334</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Single-arm cohort study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY88-8223)</intervention_name>
    <description>An alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically or cytologically confirmed castration resistant
        adenocarcinoma of the prostate with bone metastases for whom the treatment decision to
        Radium-223 has been made independent from and before patient enrolment in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment decision to Radium-223 needs to be made independent from and before patient
             enrollment in the study

          -  Histologically or cytologically confirmed castration resistant adenocarcinoma of the
             prostate with bone metastases

          -  Signed informed consent

        Exclusion Criteria:

          -  Previously treated with Radium-223 for any reason

          -  Currently treated in clinical trials including other Radium-223 studies

          -  Planned for the systemic concomitant use of other radiopharmaceuticals for treatment
             of prostate cancer or for other use
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radium-223</keyword>
  <keyword>Metastatic castration-resistant prostate cancer</keyword>
  <keyword>CRPC</keyword>
  <keyword>Phase IV</keyword>
  <keyword>Safety study</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
